IND Safety Reporting Rule Delayed After PhRMA Asks For More Harmonization
Executive Summary
FDA has made the unusual decision to delay implementation of its new IND safety reporting rules, saying it will "exercise enforcement discretion" on the matter until Sept. 28 following a meeting with the Pharmaceutical Research and Manufacturers of America.